Nanoparticle-based Methionine and AICAR delivery Elicits Robust Antitumor Immune Response.

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B209
Abstract ID: 4871

Presenting Author:
YE GU , M.S. & PhD student at Yeungnam University

Abstract:

Immunotherapeutic strategies utilizing nanoparticle-based drug delivery systems have emerged as promising approaches for cancer treatment. Previously we have reported that intratumoral injection of methionine and AICAR supplementation enhance antitumor immunity by targeting PD1 in CD4 T cells. To apply this treatment to clinical, an artificial HAS nanoparticle was developed to deliver methionine, AICAR for targeted intervention in the tumor. Our results demonstrate that the nanoparticle effectively delivered methionine and AICAR to the tumor site, resulting reduction in tumor size. Concomitant with tumor regression, nanoparticle induced a robust activation of CD4 T cells, accompanied by a significant elevation in CD69 expression and IFN-γ secretion. Notably, a concomitant reduction in PD1 expression was observed in CD4 T cells, suggesting a mitigation of immune exhaustion and enhanced effector function. Furthermore, our study revealed a synergistic anti-tumor effect when the nanoparticle was combined with anti-PD1 treatment, demonstrated superior efficacy compared to individual interventions. These findings underscore the potential of nanoparticle-based methionine and AICAR delivery as an effective approach to modulate the tumor microenvironment and activate anti-tumor immune responses. The observed synergy with anti-PD1 therapy highlights the translational potential of this combinatorial strategy for future clinical applications in cancer immunotherapy.